Usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury

A technology of acute lung injury and pirfenidone, applied in the field of treatment of liver injury necrosis and acute lung injury, pirfenidone, can solve the problem of reducing mortality

Active Publication Date: 2005-11-30
BEIJING CONTINENT PHARM CO LTD
View PDF6 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report of pirfenidone treating liver injury necrosis and acute lung injury before the present invention
[0021] In summary, there is currently a lack of limited treatment methods for liver injury necrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury
  • Usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury
  • Usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Mortality in rats with DMN-induced liver injury decreased after pirfenidone treatment

[0065] DMN (Dimethylformamide, Dimethylformamide) is a common chemical substance that causes liver damage, manifested as toxic liver disease, and severe cases lead to acute necrotizing hepatitis, with a dire prognosis.

[0066] Injury hepatitis model in rats was induced by DMN, and the method was as follows: intraperitoneal injection of 1% DMN, 10 mg / Kg, twice a week, continuously for 4 or 8 weeks.

[0067] From the 0th day of model establishment, pirfenidone was administered orally, at a dose of 250 mg / Kg, for 4 or 8 consecutive weeks. The body weight and mortality of the rats were observed.

[0068] The results showed that DMN treatment could cause weight loss and death in rats. After administration of pirfenidone, the body weight can be kept normal, and the mortality rate of animals can be significantly reduced, which is significantly different from that of the control group. (...

Embodiment 2

[0070] Pirfenidone in anti-hepatitis pharmacodynamic animal models

[0071] The experimental method is the same as above. The blood of the experimental animals was taken to separate the serum, and the AST (aspartate aminotransferase) and ALT (alanine aminotransferase) were measured; the liver tissue was taken for pathological examination.

[0072] result:

[0073] At the 4th week of the experiment, hepatic necrosis, hemorrhage, collagen deposition, and perisinus fibrosis were evident in the model group; at 8 weeks, fibrosis was formed after the necrosis of the central venous pericytes, inflammatory cell infiltration in local lesions, and new hemorrhage outwards and large pieces of necrosis ( figure 2 , 3 ). The lesion degree of the pirfenidone treatment group was significantly reduced compared with the model group, a small amount of collagen deposition after necrosis was occasionally seen around the central vein, the necrosis and inflammation of the central vein area were...

Embodiment 3

[0076] Significant effect of pirfenidone on acute lung injury

[0077] In this example, the study on the therapeutic effect of pirfenidone was carried out in rat animal models of lung injury caused by bleomycin and acute lung injury caused by fibrosis and oleic acid. It was found that pirfenidone had a significant effect on experimental lung injury in rats induced by bleomycin and oleic acid. Daily oral administration of 25mg / kg pirfenidone to rats can significantly reduce lung inflammation and relieve lung injury.

[0078] animal model

[0079] Bleomycin (B) model: long-term use of bleomycin can lead to pulmonary fibrosis. Early alveolar wall Cap permeability increases, alveolar and interstitial edema, forming interstitial lungs, and then alveolar and interstitial cellulose exudates, hyaline membrane forms, alveolar atypical hyperplasia and distal epithelial cell squamous metaplasia , the advanced stage shows extensive fibrosis of the alveoli and interstitium, so it is wid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury, more specifically the invention relates to the application of pirfenidone in abatement of symptoms for patients with hepatic injury, necrosis and acute lung injury, and in lowering mortality rate. The invention also provides the medicinal composition for treating hepatic injury, necrosis and acute lung injury.

Description

technical field [0001] The invention relates to the field of medicines, and more specifically relates to the new application of pirfenidone for treating liver injury necrosis and acute lung injury. Background technique [0002] The liver is the largest organ in the body. It has extremely important functions of digestion and metabolism, detoxification, reutilization of metabolites, and maintenance of individual internal state stability. Its metabolic activities are very complex. It not only plays an important role in substance metabolism with biosynthesis and degradation functions, but also is a storehouse of nutrients. The liver contains a special enzyme system that has the function of detoxification and is also the control station of endocrine, which can degrade many hormones passing through the blood flow of the liver. During the whole human life process, some foreign substances (such as poisons, drugs, carcinogens) often enter the body, and some biologically active subst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/44
Inventor 吴骏
Owner BEIJING CONTINENT PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap